Clinical Trial Update: Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 2/Phase 3 study comparing weekly oral lepetegravir and lenacapavir pacfosacil against Biktarvy in people with virologically su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• Lenacapavir Pacfosacil
• Lepetegravir

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-Infection | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING